MIPI (Mantle Cell)

About MIPI (Mantle Cell)

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is an essential prognostic tool meticulously developed for patients diagnosed with Mantle Cell Lymphoma (MCL). It objectively evaluates a combination of clinical and laboratory parameters, including age, performance status, lactate dehydrogenase (LDH), and white blood cell count. By integrating these factors, MIPI accurately stratifies patients into distinct low, intermediate, and high-risk groups. This stratification is critical for clinicians and oncologists to predict disease course, guide individualized treatment strategies, and facilitate informed patient counseling. The MIPI provides a standardized framework for risk assessment, optimizing therapeutic approaches and enhancing the design of clinical trials for MCL.